The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors.
P. LoRusso
Consultant or Advisory Role - IDSC - NCI
Research Funding - NCI
J. J. Ji
No relevant relationships to disclose
J. Li
No relevant relationships to disclose
L. K. Heilbrun
No relevant relationships to disclose
G. Shapiro
Research Funding - NCI
E. A. Sausville
Research Funding - NCI
S. A. Boerner
No relevant relationships to disclose
D. W. Smith
No relevant relationships to disclose
M. J. Pilat
No relevant relationships to disclose
J. Zhang
No relevant relationships to disclose
A. P. Chen
No relevant relationships to disclose
N. Nechiporchik
No relevant relationships to disclose
R. E. Parchment
No relevant relationships to disclose